Novo Nordisk and Janssen Sign an Agreement
- By BSTQ Staff
Novo Nordisk has signed an agreement with Janssen Biotech Inc. for Janssen to acquire an exclusive global license to further develop and commercialize a clinical program focused on therapy within autoimmune diseases.